Company / Shareholders' Equity
Intellia Therapeutics, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$671.4M
FY2025
5-year range
$671.4M / $1.2B
FY2021-FY2025
Trend
-23.0%
vs FY2024
Sector context
#101 of 166
Health Care
What the data says
At $671M, Intellia Therapeutics, Inc.'s shareholders' equity ranks #101 of 166 in the Health Care sector. Shareholders' Equity has declined for 3 consecutive years, from $1.2B in FY2022 to $671M in FY2025.
Based on SEC 10-K filings.
$671M in FY2025 with a 5-year CAGR of +5.0%.
Declined from $1.1B to $671M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -18.4%
- 5-Year CAGR
- +5.0%
- 10-Year CAGR
- -
Sector benchmark
#101 of 166 in Health CareTop 61% of 166This company $671.4M Sector average $5.3B
▼
-87.2% below sector average
Key checks
Key Insights
- Intellia Therapeutics, Inc.'s shareholders' equity has declined for 3 consecutive years.
- 5-year CAGR of +5.0%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 23.0% year-over-year.
- Ranks #101 out of 166 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $671.4M | -23.0% |
| FY2024 | $872.0M | -17.0% |
| FY2023 | $1.1B | -15.0% |
| FY2022 | $1.2B | +18.8% |
| FY2021 | $1.0B | +97.4% |
| FY2020 | $527.1M | +95.3% |
| FY2019 | $269.9M | -2.9% |
| FY2018 | $277.9M | -7.5% |
| FY2017 | $300.6M | +43.3% |
| FY2016 | $209.8M | +1089.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026